Hosted on MSN3mon
Amneal gets FDA approval for generic Byetta, resubmits DHE NDAAmneal Pharmaceuticals (NASDAQ:AMRX) has received FDA approval for its generic version of the GLP-1 agonist diabetes drug Byetta and resubmitted its New Drug Application for a prefilled syringe ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback